Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 11/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.79 |
| ▸ | MAPT | P10636 | 9/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.79 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.79 |
| ▸ | TP53 | P04637 | 6/20 | 0.79 |
| ▸ | RECQL | P46063 | 6/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | HPGD | P15428 | 6/20 | 0.79 |
| ▸ | CDK2 | P24941 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | CASP1 | P29466 | 4/20 | 0.79 |
| ▸ | CASP7 | P55210 | 4/20 | 0.79 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.79 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.79 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fisetin SCHEMBL29381611 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL116861 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL39454 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29394036 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL29349742 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL2281134 | 0.88 | MEN1 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| Fisetin SCHEMBL4263659 | 0.87 | CDK5 (1.00) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL10037939 | 0.86 | MEN1 (0.76) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL7660823 | 0.86 | MEN1 (0.68) | MEN1KMT2ACYP3A4HSD17B10KDM4E | |
| SCHEMBL7652737 | 0.86 | MEN1 (0.68) | MEN1KMT2ACYP3A4HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20160367497-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY | 2016-12-22 | — | — | US | claimed |
| EP-2670404-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | The Trustees of Princeton University (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2012106509-A1 | SIRTUIN MODULATORS AS VIRUS PRODUCTION MODULATORS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-08-09 | — | — | WO | claimed |
| US-20100047177-A1 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2010-02-25 | — | — | US | claimed |
| EP-2124985-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2009-12-02 | — | — | EP | claimed |
| EP-1991205-A1 | OCULAR THERAPY USING SIRTUIN-ACTIVATING AGENTS | Allergan, Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| WO-2008091710-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2008-07-31 | — | — | WO | claimed |
| WO-2007103960-A1 | OCULAR THERAPY USING SIRTUIN-ACTIVATING AGENTS | ALLERGAN, INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070212395-A1 | Ocular therapy using sirtuin-activating agents | ALLERGAN, INC. (US) | 2007-09-13 | — | — | US | claimed |
| EP-1755391-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2007-02-28 | — | — | EP | claimed |
| US-20060084135-A1 | Compositions for manipulating the lifespan and stress response of cells and organisms | BIOMOL INTERNATIONAL, INC. | 2006-04-20 | — | — | US | claimed |
| US-20060002914-A1 | treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent (such as NAD, NADH) that increases sirtuin activity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | claimed |
| WO-2006001982-A2 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES | WASHINGTON UNIVERSITY (US) | 2006-01-05 | — | — | WO | claimed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | claimed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | claimed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-1109800-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LIMITED (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012496-A1 | NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE | LG CHEMICAL LTD. (KR) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MEN1 1105/4885KMT2A 4260/4885CYP3A4 4828/4885 |
| US-20070212395-A1 | Ocular therapy using sirtuin-activating agents | SIRT1, SIRT2, SIRT7 | MEN1 3456/4885KMT2A 642/4885CYP3A4 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.